Head-to-head comparison
Nouri vs Nova MD
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Nouri is a DTC telehealth platform offering compounded semaglutide and tirzepatide bundled with nutrition and movement planning plus clinician messaging — lifestyle support included rather than upsold, on a three-rung price card with a 30-day money-back guarantee.
$175/mo sema · $175/mo (6-month prepay) tirz · Verified August 2026
Marked down on: Tirzepatide's only published figure is a six-month commitment — '$175/month ($1,050 every six months)' — so the same $175/mo headline means 'no commitment' for semaglutide and 'a half-year paid up front' for tirzepatide, on the same page
Desk Score
Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules.
$175/mo sema · $225/mo tirz · Verified July 2026
Marked down on: Legal entity name and state of incorporation not disclosed
FDAWarning letter issued to Try Nova in September 2025. See the FDA warning-letter database.
Nouri takes this head-to-head with the higher Desk Score, 76/100 (C) against 65/100 (C) for Nova MD. Nova MD still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Nouri
76/100
C
Nova MD
65/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Nouri | Nova MD |
|---|---|---|
| Semaglutide | $175/mo$175/mo month-to-month ($145/mo on the 3-month plan at $435 every three months; $120/mo on the 6-month plan at $720 every six months; compounded) | $175/mo$175/mo (compounded) |
| Tirzepatide | $175/mo6-month prepay$175/mo on the 6-month plan ($1,050 every six months; the month-to-month rate is not published, compounded) | $225/mo$225/mo (compounded) |
| Coverage | All 50 states | Not listed on Nova MD's site (checked July 2026) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | People who want coaching and clinician access included and are willing to commit six months to get the guarantee — semaglutide is the clear product here. | Lowest 3-month compounded pricing with an explicit microdose program. |
| Desk Score | 76/100C | 65/100C |
The verdict
Desk pick — NouriNouri takes this head-to-head with the higher Desk Score, 76/100 (C) against 65/100 (C) for Nova MD. Nova MD still holds its ground where its strengths line up with yours.
Choose Nouri if…
People who want coaching and clinician access included and are willing to commit six months to get the guarantee — semaglutide is the clear product here.
$175/mo sema · $175/mo (6-month prepay) tirz · All 50 states
Choose Nova MD if…
Lowest 3-month compounded pricing with an explicit microdose program.
$175/mo sema · $225/mo tirz
FDAWarning letter issued to Try Nova in September 2025. See the FDA warning-letter database.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Nouri · Nova MD.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Nouri
- CoreAge Rx vs Nova MD
- Nouri vs Trimi
- Nova MD vs Trimi
- Elara Health and Wellness vs Nouri
- Elara Health and Wellness vs Nova MD
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.